- Local
- Community
- Journalism
Support the independent voice of Dallas and help keep the future of Dallas Observer free.
Edson Sherwood Brown, an associate professor of psychiatry at UT Southwestern Medical Center, says he's come up with a new cure for those cocaine cravings: quetiapine. Whassat? Well, it's better known by its brand name, Seroquel, and it since its Federal Drug Administration approval a decade ago, it's been sold as an antipsychotic used to treat patients suffering from schizophrenia and bipolar disorder.
But according to this patent issued last week by the U.S. Parent and Trademark Office, Brown has come up with "a method of treating cocaine dependence comprising of administering an effective amount of a composition comprising quetiapine or a pharmaceutically acceptable salt thereof to reduce cocaine cravings in a patient in need of treatment of cocaine dependence, wherein said quetiapine is a sole active agent."
Brown -- who heads the Psychoneuroendocrine Research Group at UT Southwestern, which studies substance abuse -- doesn't get the patent, though. That goes to AstraZeneca, the Swedish pharmaceutical company that makes the drug. --Robert Wilonsky
Keep the Dallas Observer Free... Since we started the Dallas Observer, it has been defined as the free, independent voice of Dallas, and we would like to keep it that way. Offering our readers free access to incisive coverage of local news, food and culture. Producing stories on everything from political scandals to the hottest new bands, with gutsy reporting, stylish writing, and staffers who've won everything from the Society of Professional Journalists' Sigma Delta Chi feature-writing award to the Casey Medal for Meritorious Journalism. But with local journalism's existence under siege and advertising revenue setbacks having a larger impact, it is important now more than ever for us to rally support behind funding our local journalism. You can help by participating in our "I Support" membership program, allowing us to keep covering Dallas with no paywalls.